← ANALYST RATINGS · TIPRANKS
Zenas BioPharma, Inc. (ZBIO): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy1 Hold0 Sell
Ratings of 5 analysts in the last 3 months12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $44.80, the highest $55.00, the lowest $32.00. The average is +80.4% from the last price of $24.84.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $27.00 → $26.00−3.7% | Hold | +4.7% | Reiterated | 13.10.26on TipRanks 11:07 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $27.00 → $26.00−3.7% | Hold | +4.7% | Reiterated | 13.10.26on TipRanks 11:07 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $27.00 → $26.00−3.7% | Hold | +4.7% | Reiterated | 13.10.26on TipRanks 11:07 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $26.00 → $25.00−3.8% | Sell | +0.6% | Reiterated | 13.10.26on TipRanks 11:07 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $27.00 → $25.00−7.4% | Hold | +0.6% | Reiterated | 13.10.26on TipRanks 11:07 | — | |
| Unknown Analyst | Wedbush | $45.00 | Buy | +81.2% | Reiterated | 13.10.26on TipRanks 11:07 | −4.7%next day −0.1% | ↗ |
| Matthew Caufield★★★★★★★★★★#1718 · hits 42% · avg +10.1% | H.C. Wainwright | $44.00 | Buy | +77.1% | Reiterated | 13.10.26on TipRanks 06:30 | −4.7%next day −0.1% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $48.00 | Buy | +93.2% | Reiterated | 12.10.26on TipRanks 17:58 | −4.7%next day −0.1% | ↗ |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $26.00 → $27.00+3.8% | Hold | +8.7% | Reiterated | 12.10.26on TipRanks 00:05 | — | |
| Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% | Morgan Stanley | $22.00 → $32.00+45.5% | Hold | +28.8% | Reiterated | 17.08.26on TipRanks Aug 14 08:35 | +1.3%next day +3.8% · 5 days +10.8% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $55.00 | Buy | +121.4% | Reiterated | 13.08.26on TipRanks Aug 14 08:15 | −7.4%next day +1.3% · 5 days +10.3% | ↗ |
| Cory Kasimov★★★★★★★★★★#276 · hits 59% · avg +18.9% | Evercore ISI | $55.00 | Buy | +121.4% | Reiterated | 17.03.26on TipRanks 09:45 | +0.8%next day −0.5% · 5 days −7.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Zenas BioPharma, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $44.80 at a price of $26.97 (+66.1%); now: $44.80 at $24.84 (+80.4%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 7 | 7 | 6 | 4 | 8 |
| Buy | 0 | 0 | 0 | 1 | 3 | 3 |
| Hold | 3 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 18.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.24 (from $-1.31 to $-1.08). Last quarter: $-1.77.
Sales
Next quarter’s sales estimate — $0M (from $0M to $0M). Last quarter: $1M.
Best top-analyst consensus in the sector · Healthcare
About Zenas BioPharma, Inc.
- CEO: Leon Oliver Moulder Jr.
- Employees: 167
- 852 Winter Street, Waltham, MA, 02451, US
- zenasbio.com
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Data from the stock’s TipRanks forecast page, read 97 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗